
Lupin Limited, a global pharmaceutical company, has launched Vilfuro-G®, the world’s first fixed-dose triple combination drug for managing chronic obstructive pulmonary disease (COPD) in India. The Drug Controller General of India approved the Dry Powder Inhaler product, uniquely combining Vilanterol, Fluticasone Furoate, and Glycopyrronium Bromide for long-term treatment of moderate to severe COPD. With over 37 million COPD patients in India, this innovation addresses a leading cause of death and disability. Lupin aims to expand its respiratory portfolio, providing healthcare solutions and transforming lives amid the surging global prevalence of COPD.
Like
Save
Share